Skip Navigation


Annals of Oncology Advance Access originally published online on June 14, 2005
Annals of Oncology 2005 16(9):1498-1502; doi:10.1093/annonc/mdi281
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
16/9/1498    most recent
mdi281v1
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (1)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Di Lauro, L.
Right arrow Articles by Lopez, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Di Lauro, L.
Right arrow Articles by Lopez, M.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2005 European Society for Medical Oncology

Epirubicin, cisplatin and docetaxel combination therapy for metastatic gastric cancer

L. Di Lauro1,*, F. Belli2, M. G. Arena3, S. Carpano1, G. Paoletti1, D. Giannarelli4 and M. Lopez1

1 Division of Medical Oncology B and 4 Biostatistics Unit, ‘Regina Elena’ Institute for Cancer Research, Rome 2 Oncology Service, San Giuseppe Hospital, Albano Laziale 3 Oncology Service, Toraldo Hospital, Tropea, Italy

* Correspondence to: Dr L. Di Lauro, Division of Medical Oncology B, Regina Elena Institute for Cancer Research, Via Elio Chianesi, 53, 00144 Rome, Italy. Tel: +39-06-52666762; Fax: +39-06-52665075; Email: dilauro{at}ifo.it

Background: Docetaxel is a new agent with activity in metastatic gastric cancer. This phase II study was designed to evaluate the activity and safety of an epirubicin, cisplatin and docetaxel combination in patients with this disease.

Patients and methods: Forty-six patients with gastric adenocarcinoma with measurable distant metastasis were eligible for the study. Patients received epirubicin 50 mg/m2 and docetaxel 60 mg/m2, on day 1, and cisplatin 60 mg/m2 on day 2. Granulocyte colony-stimulating factor 300 µg/day subcutaneously was given on days 5 and 6. Cycles were repeated every 3 weeks for a maximum of eight courses.

Results: All patients were evaluable for response and toxicity. Two complete and 21 partial responses were observed, with an overall response rate of 50% [95% confidence interval (CI) 36% to 64%]. Stable disease was observed in 13 patients (28%) and progressive disease in 10 patients (22%). The median time to progression was 6 months (95% CI 5–7) and the median overall survival was 11.2 months (95% CI 8.5–13.9). Grade 3/4 neutropenia, thrombocytopenia and anemia occurred in 46%, 7% and 13% of patients, respectively. There were five episodes of febrile neutropenia in four patients. Other grade 3 toxicities included mucositis in three patients (6.5%), vomiting in four patients (8.7%) and diarrhea in one patient (2%). There were no cardiac toxicity, severe neurotoxicity or treatment-related deaths.

Conclusions: The epirubicin, cisplatin and docetaxel combination is an active and well tolerated novel chemotherapy regimen for treating metastatic gastric cancer and deserves further evaluation in randomized studies.

Key words: cisplatin, docetaxel, epirubicin, metastatic gastric cancer


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.